About concomitant KRAS and other molecular alterations in non-small cell lung cancers.

作者信息

Bourhis Amélie, Quintin-Roué Isabelle, Uguen Arnaud

机构信息

CHRU Brest, Service d'anatomie et cytologie pathologiques, Brest, F-29200, France.

CHRU Brest, Service d'anatomie et cytologie pathologiques, Brest, F-29200, France; Inserm U1053 BaRITOn, Bordeaux, F-33076, France.

出版信息

Hum Pathol. 2019 May;87:115-116. doi: 10.1016/j.humpath.2019.01.003. Epub 2019 Feb 20.

DOI:10.1016/j.humpath.2019.01.003

PMID:30796937

Abstract

摘要

相似文献

About concomitant KRAS and other molecular alterations in non-small cell lung cancers.

Hum Pathol. 2019 May;87:115-116. doi: 10.1016/j.humpath.2019.01.003. Epub 2019 Feb 20.

EGFR and KRAS molecular genotyping for pulmonary carcinomas: Feasibility of a simple and rapid technique implementable in any department of pathology.肺癌的表皮生长因子受体（EGFR）和 Kirsten 大鼠肉瘤病毒癌基因（KRAS）分子基因分型：一种可在任何病理科实施的简单快速技术的可行性

Pathol Res Pract. 2017 Jul;213(7):793-798. doi: 10.1016/j.prp.2017.03.011. Epub 2017 Mar 30.

EGFR, KRAS, BRAF and HER2 testing in metastatic lung adenocarcinoma: Value of testing on samples with poor specimen adequacy and analysis of discrepancies.转移性肺腺癌中表皮生长因子受体（EGFR）、 Kirsten 大鼠肉瘤病毒癌基因（KRAS）、 B-Raf 原癌基因（BRAF）和人表皮生长因子受体2（HER2）检测：对标本质量欠佳的样本进行检测的价值及差异分析

Exp Mol Pathol. 2017 Dec;103(3):306-310. doi: 10.1016/j.yexmp.2017.11.013. Epub 2017 Nov 22.

Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.在接受铂类双联化疗的新诊断IV期非小细胞肺癌患者中，根据KRAS突变状态得出的生存结果。

Oncotarget. 2015 Oct 6;6(30):30287-94. doi: 10.18632/oncotarget.4711.

ROS1-rearranged Non-Small Cell Lung Cancers With Concomitant Oncogenic Driver Alterations: About Some Rare Therapeutic Dilemmas.伴有致癌驱动基因改变的ROS1重排非小细胞肺癌：关于一些罕见的治疗困境

Clin Lung Cancer. 2018 Jan;19(1):e73-e74. doi: 10.1016/j.cllc.2017.08.005. Epub 2017 Sep 1.

[Detection and Analysis of EGFR and KRAS Mutation with Lung Adenocarcinoma].[肺腺癌中表皮生长因子受体（EGFR）和 Kirsten 大鼠肉瘤病毒癌基因（KRAS）突变的检测与分析]

Zhongguo Fei Ai Za Zhi. 2015 Nov;18(11):686-90. doi: 10.3779/j.issn.1009-3419.2015.11.05.

MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status.根据表皮生长因子受体（EGFR）、 Kirsten大鼠肉瘤病毒癌基因（KRAS）和间变性淋巴瘤激酶（ALK）状态分析肺腺癌中的微小RNA表达谱及其临床病理意义

Oncotarget. 2017 Jan 31;8(5):8484-8498. doi: 10.18632/oncotarget.14298.

Molecular analysis of peripheral lung adenocarcinoma in brush cytology obtained by EBUS plus fluoroscopy-guided bronchoscopy.经 EBUS 加透视引导支气管镜刷取的外周型肺腺癌的分子分析。

Cancer Cytopathol. 2018 Oct;126(10):860-871. doi: 10.1002/cncy.22053. Epub 2018 Oct 6.

The clinicopathological significance of ALK rearrangements and KRAS and EGFR mutations in primary pulmonary mucinous adenocarcinoma.ALK重排以及KRAS和EGFR突变在原发性肺黏液腺癌中的临床病理意义

Tumour Biol. 2015 Aug;36(8):6417-24. doi: 10.1007/s13277-015-3331-4. Epub 2015 Mar 28.

Response to comment on "Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes".对“KRAS突变亚型和并发致病突变对非小细胞肺癌预后的影响”评论的回应

Lung Cancer. 2019 Nov;137:159-160. doi: 10.1016/j.lungcan.2019.08.020. Epub 2019 Aug 26.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验